Agios Pharmaceuticals Inc to Review the Rise up Phase 2 Data and next Steps for the Phase 3 Portion of the Study Call Transcript
Good morning and welcome to then Agios' webcast and conference call. (Operator Instructions) Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Agios' Chief Financial Officer, Cecilia Jones.
Thank you, operator. Good morning, everyone, and welcome to Agios' webcast to announce top line results from the Phase II RISE UP Study of mitapivat in patients with sickle cell disease. You can access slides for today's call by going to the Investors section of our website, agios.com.
On today's call, I am joined by our Chief Executive Officer, Brian Goff; Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development; Dr. Ahmar Zaidi, Agios' Medical Director, Clinical Development and Research; and Tsveta Milanova, our Chief Commercial Officer.
Before we get started, I would like to remind everyone that some of our statements -- we make some of the statements we make on this call will include forward-looking statements. Actual
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |